1
|
Stepanishyna Y, Manni M, Civallero M, Shokun N, Skrypets T, Burtna A, Shapovalenko N, Tytorenko I, Aleksyk O, Pastushenko Y, Gubareva H, Moiseienko K, Kadnikova T, Rudyuk T, Filonenko K, Martynchyk A, Novosad O, Galli GR, Kryachok I, Federico M. Outcome of malignant lymphoma in Ukraine. Analysis of 563 cases registered in the Ukrainian Lymphoma Registry in 2019-2021. Br J Haematol 2024; 204:1757-1761. [PMID: 38400556 DOI: 10.1111/bjh.19352] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2024] [Revised: 02/05/2024] [Accepted: 02/10/2024] [Indexed: 02/25/2024]
Abstract
We report the outcome of 563 cases of newly diagnosed lymphoma registered in 2019-2021, including 176 cases (31.2%) of Hodgkin lymphoma (HL), 130 (23.1%) of diffuse large B-cell lymphoma (DLBCL), 28 (5%) of follicular lymphoma (FL), 16 (2.9%) of mantle cell lymphoma (MCL) and 20 (3.5%) of peripheral T-cell lymphoma (PTCL). After a median follow-up of 30.1 months (95% CI: 28.8-31.3), the 3-year overall survival rates were 95%, 83%, 86%, 100%, 61% and 42% for HL, DLBCL, CLL, FL, MCL and PTCL respectively. These data offer valuable information on the curability of lymphoma patients in Ukraine, in a real-world setting.
Collapse
Affiliation(s)
- Yana Stepanishyna
- Department of Bone Marrow Transplant, National Cancer Institute, Kyiv, Ukraine
- Department of Hematology, Jules Bordet Institute, Brussels, Belgium
| | - Martina Manni
- Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy
| | - Monica Civallero
- Surgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy
| | - Nazar Shokun
- Department of Bone Marrow Transplant, National Cancer Institute, Kyiv, Ukraine
| | - Tetiana Skrypets
- Hematology Unit, IRCCS Istituto Tumori 'Giovanni Paolo II', Bari, Italy
| | - Alevtyna Burtna
- Department of Bone Marrow Transplant, National Cancer Institute, Kyiv, Ukraine
| | | | - Iryna Tytorenko
- Department of Oncohematology, National Cancer Institute, Kyiv, Ukraine
| | - Olena Aleksyk
- Department of Oncohematology, National Cancer Institute, Kyiv, Ukraine
| | - Yan Pastushenko
- Department of Oncohematology, National Cancer Institute, Kyiv, Ukraine
| | - Hanna Gubareva
- Department of medical statistics and national cancer register, National Cancer Institute, Kyiv, Ukraine
| | - Kateryna Moiseienko
- Department of Bone Marrow Transplant, National Cancer Institute, Kyiv, Ukraine
| | - Tetyana Kadnikova
- Department of Oncohematology, National Cancer Institute, Kyiv, Ukraine
| | - Timur Rudyuk
- Department of Oncohematology, National Cancer Institute, Kyiv, Ukraine
| | - Kateryna Filonenko
- Department of Hematology and Transplantology, University Clinical Center, Gdansk, Poland
| | | | - Olga Novosad
- Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| | - Giulia R Galli
- Department of Biological and Environmental Sciences and Technologies, University of Salento, Lecce, Italy
| | - Irina Kryachok
- Department of Oncohematology, National Cancer Institute, Kyiv, Ukraine
| | - Massimo Federico
- Surgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy
| |
Collapse
|
2
|
Kozhukhov S, Dovganych N, Smolanka I, Kryachok I, Kovalyov O. Cancer and War in Ukraine. JACC CardioOncol 2022; 4:279-282. [PMID: 35818540 PMCID: PMC9270614 DOI: 10.1016/j.jaccao.2022.04.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Affiliation(s)
- Sergey Kozhukhov
- Cardio-Oncology Center, Clinical Pharmacology and Cardio-Oncology Department, National Scientific Center M.D. Strazhesko Institute of Cardiology, Kyiv, Ukraine
- Address for correspondence: Dr Sergey Kozhukhov, National Scientific Center M.D. Strazhesko Institute of Cardiology, Clinical Pharmacology and Cardio-Oncology Department, 5, Narodnogo Opolchenia Street, Kyiv 03680, Ukraine.
| | - Nataliia Dovganych
- Cardio-Oncology Center, Clinical Pharmacology and Cardio-Oncology Department, National Scientific Center M.D. Strazhesko Institute of Cardiology, Kyiv, Ukraine
| | - Ivan Smolanka
- Breast Cancer Department, Ukrainian National Cancer Institute, Kyiv, Ukraine
| | - Irina Kryachok
- Onco-Hematology Department, Ukrainian National Cancer Institute, Kyiv, Ukraine
| | - Olexiy Kovalyov
- Oncology Department, Zaporizhia Medical Academy of Post-Graduate Education, Zaporizhia, Ukraine
| |
Collapse
|
3
|
Federico M, Chiattone CS, Prince HM, Pavlovsky A, Manni M, Civallero M, Skrypets T, De Souza CA, Hawkes EA, Fiad L, Lymboussakis A, Tomuleasa C, Nair R, Pereira J, Pereyra P, Minoia C, Kryachok I, de Castro NS, Advani RH, Luminari S. SUBTYPES OF MATURE T AND NK CELL LYMPHOMAS ACCORDING TO 2016 WHO CLASSIFICATION. PRELIMINARY REPORT OF THE INTERNATIONAL PROSPECTIVE T‐CELL PROJECT 2.0. Hematol Oncol 2021. [DOI: 10.1002/hon.135_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- M Federico
- University of Modena and Reggio Emilia, Surgical Medical and Dental Department of Morphological Sciences related to Transplant Oncology and Regenerative Medicine Modena Italy
| | - C. S Chiattone
- Santa Casa de Sao Paulo School of Medical Sciences São Paulo Brazil
| | - H. M Prince
- Epworth Healthcare, East Melbourne Richmond Australia
| | - A Pavlovsky
- Fundaleu, Haematology Buenos Aires Argentina
| | - M Manni
- University of Modena and Reggio Emilia, Surgical Medical and Dental Department of Morphological Sciences related to Transplant Oncology and Regenerative Medicine Modena Italy
| | - M Civallero
- University of Modena and Reggio Emilia, Surgical Medical and Dental Department of Morphological Sciences related to Transplant Oncology and Regenerative Medicine Modena Italy
| | - T Skrypets
- University of Modena and Reggio Emilia, Surgical Medical and Dental Department of Morphological Sciences related to Transplant Oncology and Regenerative Medicine Modena Italy
| | | | - E. A Hawkes
- Lymphoma and Related Diseases Registry School of Public Health and Preventive Medicine Monash University and Olivia Newton John Cancer Research Institute Austin Health, Melbourne Australia
| | - L Fiad
- Hospital Italiano La Plata Department of Hematology and Oncology Buenos Aires Argentina
| | - A Lymboussakis
- University of Modena and Reggio Emilia, Surgical Medical and Dental Department of Morphological Sciences related to Transplant Oncology and Regenerative Medicine Modena Italy
| | - C Tomuleasa
- Ion Chiricuta Oncology Institute Department of Hematology Cluj Napoca Romania
| | - R Nair
- TATA Medical Center, Clinical Haematology Oncology Kolkata India
| | - J Pereira
- Universidade de São Paulo Hospital das Clínicas da Faculdade de Medicina São Paulo Brazil
| | - P Pereyra
- Hospital Nacional Dr. Prof. Alejandro Posadas Hematology Buenos Aires Argentina
| | - C Minoia
- IRCCS Cancer Institute "Giovanni Paolo II" Haematology Unit Bari Italy
| | - I Kryachok
- National Cancer Institute Oncohematology Department Kiev Ukraine
| | - N. S de Castro
- Hospital de Cancer de Barretos, Hematology, Barretos São Paulo Brazil
| | - R. H Advani
- Stanford Cancer Center Blood and Marrow Transplant Program, Stanford California USA
| | - S Luminari
- Azienda Unità Sanitaria Locale IRCCS, Arcispedale Santa Maria Nuova IRCCS, Hematology Unit and University of Modena and Reggio Emilia, Surgical Medical and Dental Department of Morphological Sciences related to Transplant Oncology and Regenerative Medicine Reggio Emilia Italy
| |
Collapse
|
4
|
Martelli M, Zucca E, Botto B, Kryachok I, Ceriani L, Balzarotti M, Tucci A, Cabras MG, Zilioli VR, Rusconi C, Angrilli F, Arcaini L, Iwanicka AD, Ferreri A, Merli F, Zhao W, Hodgson D, Ionescu C, Fosså A, Cwynarski K, Mikhaeel G, Jerkeman M, Janikova A, Hüttmann A, Ciccone G, Metser U, Barrington S, Malkowski B, Versari A, Esposito F, Cozens K, Ielmini N, Ricardi R, Cavalli F, Johnson P, Davies A. IMPACT OF DIFFERENT INDUCTION REGIMENS ON THE OUTCOME OF PRIMARY MEDIASTINAL B CELL LYMPHOMA IN THE PROSPECTIVE IELSG 37 TRIAL. Hematol Oncol 2021. [DOI: 10.1002/hon.49_2879] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
5
|
Skrypets T, Ferrari C, Nassi L, Margiotta Casaluci G, Puccini B, Mannelli L, Filonenko K, Kryachok I, Clemente F, Vegliante MC, Daniele A, Sacchetti G, Guarini A, Minoia C. 18F-FDG PET/CT Cannot Substitute Endoscopy in the Staging of Gastrointestinal Involvement in Mantle Cell Lymphoma. A Retrospective Multi-Center Cohort Analysis. J Pers Med 2021; 11:jpm11020123. [PMID: 33668644 PMCID: PMC7918751 DOI: 10.3390/jpm11020123] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2021] [Revised: 02/06/2021] [Accepted: 02/10/2021] [Indexed: 12/02/2022] Open
Abstract
The detection of gastrointestinal (GI) involvement in Mantle Cell Lymphoma is often underestimated and may have an impact on outcome and clinical management. We aimed to evaluate whether baseline 18F-FDG PET/CT presents comparable results to endoscopic biopsy in the diagnosis of GI localizations. In our retrospective cohort of 79 patients, sensitivity and specificity of 18F-FDG PET/CT were low for the stomach, with a fair concordance (k = 0.32), while higher concordance with pathologic results (k = 0.65) was detected in the colorectal tract. Thus, gastric biopsy remains helpful in the staging of MCL despite 18F-FDG PET/CT, while colonoscopy could be omitted in asymptomatic patients. The validation of our data in prospective cohorts is desirable
Collapse
Affiliation(s)
- Tetiana Skrypets
- Haematology Unit, IRCCS Istituto Tumori “Giovanni Paolo II”, 70124 Bari, Italy; (T.S.); (F.C.); (M.C.V.); (A.G.)
| | - Cristina Ferrari
- D.I.M.—Diagnostic Imaging-Nuclear Medicine, University of Bari “Aldo Moro”, 70124 Bari, Italy;
| | - Luca Nassi
- Haematology Department, Azienda Ospedaliero-Universitaria Maggiore della Carità, 28100 Novara, Italy; (L.N.); (G.M.C.)
| | - Gloria Margiotta Casaluci
- Haematology Department, Azienda Ospedaliero-Universitaria Maggiore della Carità, 28100 Novara, Italy; (L.N.); (G.M.C.)
| | - Benedetta Puccini
- Hematology Department, Azienda Ospedaliera Careggi, 50139 Firenze, Italy; (B.P.); (L.M.)
| | - Lara Mannelli
- Hematology Department, Azienda Ospedaliera Careggi, 50139 Firenze, Italy; (B.P.); (L.M.)
| | - Kateryna Filonenko
- Oncohematology Department, National Cancer Institute, 03022 Kyiv, Ukraine; (K.F.); (I.K.)
| | - Irina Kryachok
- Oncohematology Department, National Cancer Institute, 03022 Kyiv, Ukraine; (K.F.); (I.K.)
| | - Felice Clemente
- Haematology Unit, IRCCS Istituto Tumori “Giovanni Paolo II”, 70124 Bari, Italy; (T.S.); (F.C.); (M.C.V.); (A.G.)
| | - Maria Carmela Vegliante
- Haematology Unit, IRCCS Istituto Tumori “Giovanni Paolo II”, 70124 Bari, Italy; (T.S.); (F.C.); (M.C.V.); (A.G.)
| | - Antonella Daniele
- Experimental Oncology and Biobank Management Unit, IRCCS Istituto Tumori “Giovanni Paolo II”, 70124 Bari, Italy;
| | | | - Attilio Guarini
- Haematology Unit, IRCCS Istituto Tumori “Giovanni Paolo II”, 70124 Bari, Italy; (T.S.); (F.C.); (M.C.V.); (A.G.)
| | - Carla Minoia
- Haematology Unit, IRCCS Istituto Tumori “Giovanni Paolo II”, 70124 Bari, Italy; (T.S.); (F.C.); (M.C.V.); (A.G.)
- Correspondence: ; Tel.: +39-0805555372
| |
Collapse
|
6
|
Miklos U, Strugov V, Lewerin C, Grosicki S, Mazur G, Steurer M, Montillo M, Kryachok I, Middeke JM, Rekhtman G, Stefanelli T, Vincent G, Govindaraju S, Österborg A. Five-year survival follow-up of a phase III randomised trial comparing ofatumumab versus physicians' choice for bulky fludarabine-refractory chronic lymphocytic leukaemia: a short report. Br J Haematol 2020; 189:689-693. [PMID: 31994178 DOI: 10.1111/bjh.16429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2019] [Accepted: 11/08/2019] [Indexed: 11/28/2022]
Abstract
In 2014, an interim analysis of a phase 3 study was performed to evaluate the effectiveness of ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukaemia (BFR CLL) as compared to physician's choice. The five-year follow-up of this phase 3 trial showed that ofatumumab therapy resulted in a numerically but not significantly longer overall survival. As only few patients had the chance to receive a kinase inhibitor later, the study displays the survival of BFR CLL patients in the period prior to receiving small-molecule inhibitors. Ofatumumab is a well-tolerable treatment option in multiresistant advanced CLL.
Collapse
Affiliation(s)
- Udvardy Miklos
- Department of Hematology, Debrecen University, Debrecen, Hungary
| | - Vladimir Strugov
- Almazov National Medical Research Centre, St. Petersburg, Russian Federation
| | - Catharina Lewerin
- Section of Hematology and Coagulation, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Sebastian Grosicki
- Department of Hematology and Cancer Prevention, Medical University of Silesia, Katowice, Poland
| | | | | | - Marco Montillo
- Department of Onco-Hematology, Division of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy
| | - Irina Kryachok
- Oncohematology, National Cancer Institute, Kyiv, Ukraine
| | - Jan M Middeke
- Medizinische Klinik I, Universitaetsklinikum C.G.Carus, Dresden, Germany
| | | | | | | | | | - Anders Österborg
- Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
| |
Collapse
|
7
|
Sokolovskaya I, Kryachok I, Chorna I, Semeniv I, Kotuza A, Hryhorieva N, Plakhotnik O, Zarytska V, Zhuravel V, Kmetyuk Y, Kondratiuk A. Influence of exogenous, physiological and factors of chronic inflammatory process on indicators of disturbances of adaptive processes of the person. Fr Ukr J Chem 2020. [DOI: 10.17721/fujcv8i2p183-202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Changes in laboratory parameters can be caused by physical, chemical, biological and other external factors, depending on physiological conditions, in most cases they have an adaptive nature, and it is not always possible to distinguish them from physiological fluctuations. At the same time, obvious shifts in laboratory parameters may indicate a violation of adaptation processes and damage of tissues and organs, despite the absence of clinical manifestations of a disease.
Collapse
Affiliation(s)
| | | | | | - Igor Semeniv
- Hospital "Feofania" the State Management of Affairs
| | | | - Nataliia Hryhorieva
- State Institution "DF Chebotareva Institute of Gerontology National Academy of Medical Sciences of Ukraine"
| | | | | | | | | | | |
Collapse
|
8
|
Novosad O, Skrypets T, Pastushenko Y, Titorenko I, Martynchyk A, Skachkova O, Inomistova M, Gorbach A, Khranovska N, Kryachok I. MAPK/ERK signal pathway alterations in patients with Langerhans Cell Histiocytosis. Klin Onkol 2018; 31:130-136. [PMID: 29708356 DOI: 10.14735/amko2018130] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND Clinical outcomes of Langerhans cell histiocytosis (LCH) are highly variable. It has been suggested that mitogen-activated protein kinase (MAPK) /extracellular signal-regulated kinases (ERK) signaling pathway might be activated in LCH patients. MATERIALS AND METHODS We investigated KRAS, BRAF and NRAS mutations in patients with LCH by qPCR. RESULTS Eight adult patients with LCH were treated at the National Cancer Institute, Kiev, Ukraine. Five patients received chemo plus radiation therapy and three patients received only chemotherapy, resp. (p < 0.05). All patients received LCH-I study protocol, six cycles in average. A BRAF c.1799T > A, p. V600E mutation was detected in 25% (2/8) of cases - 1 patient had an early relapse in 6 months, and 1 patient - stable disease. We did not find any BRAF, KRAS or NRAS mutations in three patients with late relapses (in 15, 24 and 46 months). Notably, KRAS mutations were not revealed in any LCH samples. The NRAS c.182A > G, p. Q61R mutation was found in two cases - one patient had LCH transformed to Hodgkins lymphoma, one patient had a refractory disease. Time to relapse rate (TTR) in patients with and without BRAF V600E gene mutation was 13 vs. 28 months, resp. (p < 0.05). TTR was 31.3 vs. 6.41 months in patients with absence and presence of NRAS mutation, p < 0.05. Multivariate analysis showed the presence of NRAS Q61R mutation was associated with poor event-free survival in LCH patients with HR of 6.1 (95% CI 0.2-12.6; p = 0.008). CONCLUSION BRAF and NRAS mutations in LCH suggest a possibility of the disease being driven by the activation of the MAPK/ERK pathway. These oncogenic mutations provide new opportunities in understanding LCH pathogenesis and may be a potential target of therapy.Key words: Langerhans cell histiocytosis - mutations - prognostic factors - relapse - survival.
Collapse
|
9
|
Kryachok I, Novosad O, Skrypets T, Kadnikova T, Titorenko I, Aleksik O, Filonenko K, Martynchyk A, Pastushenko Y, Stepanishina Y, Kushchevyy E, Ulianchenko K, Surkis M, Jurchishina V, Gingsburg E. Ukrainian Association for helping patients with lymphoproliferative diseases: Patients support care program. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx385.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
10
|
Skrypets T, Novosad O, Pastushenko Y, Skachkova O, Gorbach O, Khranovska N, Kryachok I. Evaluation of indoleamine 2,3-dioxygenase expression (IDO), transforming growth factor beta (TGF-β) and interleukin 13 (IL13) expression on clinical outcome in patients with Hodgkin’s lymphoma. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx373.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
11
|
Kryachok I, Martynchyk A, Filonenko K, Grabovoy A, Antoniuk S, Tytorenko I, Novosad O, Kadnikova T, Aleksik O, Stepanishyna I. The predictive value of immunohistochemical expression of Bcl-2, Bcl-6, MUM1, CD10 and CD30 in patients with diffuse large cell lymphoma. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw375.18] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
12
|
Kryachok I, Stepanishyna I, Tytorenko I, Martynchyk A, Filonenko K, Novosad O, Kadnikova T, Pastushenko I, Kushchevyy Y, Skrypets T, Aleksyk O, Ulianchenko K. R-da-EPOCH vs R-CHOP in patients with primary mediastinal large B-cell lymphoma: Results of randomised (prospective) multicenter study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw375.04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
13
|
Kryachok I, Skrypets T, Novosad O, Khranovska N, Skachkova O, Ulianchenko K, Martynchyk A, Tytorenko I, Filonenko K, Stepanishyna I, Svergun N, Gorbach O, Nevdakh O. The role of indoleamine 2,3-dioxygenase expression in diffuse large B-cell lymphoma prognosis. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw375.17] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
14
|
Stepanishyna I, Kryachok I, Titorenko I, Filonenko K, Martynchyk A, Novosad O, Sokolov V, Vereschako R. Intermediate Results of Treatment of Primary Mediastinal Large В-Cell Lymphoma with Da-Epoch-R Regimen. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu339.18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Abramenko I, Bilous N, Kryachok I, Filonenko I, Pilipenko G, Chumak A, Bazyka D, Bebeshko V. IGHV3-21 gene expression in patients with B-cell chronic lymphocytic leukemia in Ukraine. Exp Oncol 2007; 29:226-230. [PMID: 18004251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
UNLABELLED THE AIM of the study was to evaluate the frequency of IGHV3-21 gene usage and its clinical significance for patients with B-cell chronic lymphocytic leukemia (CLL) in Ukraine. PATIENTS AND METHODS Immunoglobulin variable heavy chain (IGHV) gene repertoire was studied in 189 CLL patients using reverse transcribed polymerase chain reaction and direct sequence of amplified products. RESULTS IGHV3-21 gene expression was found in 11 cases (5.8%), and its frequency was intermediate between Scandinavian (11.7%) and Mediterranean CLL (2.9%) cohorts. The most of cases (9 of 11) belonged to subset with heterogeneous HCDR3 (heteroHCDR3 subset), and only 2 cases--to subset with classical short ARDANGMDV motif (homHCDR3 subset). Six IGHV3-21 cases were mutated and 5 cases were unmutated. All unmutated cases (all were from heteroHCDR3 subset) had similarity of their HCDR3s with previously published sequences. The differences in overall (OS), progression-free (PFS) and treatment-free survival (TFS) for IGHV3-21 positive patients in comparison with CLL patients expressing the other IGHV genes were statistically insignificant. These survival parameters were comparable also for CLL patients with mutated IGHV3-21 gene usage and expression the others mutated IGHV genes. But remarkable feature of IGHV3-21 expressing patients was high incidence of solid tumors. They have developed in 4 IGHV3-21 positive cases (36.4%) and in 10 cases with expression of the others IGHV genes (5.6%, p=0.0002). Furthermore, in small group of 6 patients with mutated IGHV3-21 gene expression, 3 patients had solid tumors and one underwent Richter transformation. Unmutated IGHV3-21 gene expressed patients had worse OS and PFS in comparison with CLL patients that expressed the others unmutated IGHV genes. CONCLUSION Presented data are in agreement with the opinion about negative prognostic significance of IGHV3-21 gene expression regardless its mutation status. IGHV3-21 expression was associated with development of secondary solid tumors. Revealed high level of homology in heteroHDR3s subset might suggest about possible antigenic influence also, in addition to homHCDR3 subset that was proposed earlier.
Collapse
MESH Headings
- Adult
- Aged
- Amino Acid Sequence
- Female
- Flow Cytometry
- Gene Expression
- Gene Rearrangement, B-Lymphocyte, Heavy Chain
- Genes, Immunoglobulin Heavy Chain
- Humans
- Immunoglobulin Variable Region/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/mortality
- Male
- Middle Aged
- Molecular Sequence Data
- Mutation
- Neoplasms, Second Primary/genetics
- Prognosis
- Reverse Transcriptase Polymerase Chain Reaction
- Sequence Homology, Amino Acid
- Ukraine
Collapse
Affiliation(s)
- I Abramenko
- Scientific Centre for Radiation Medicine Academy of Medical Science of Ukraine, Kiev, Ukraine
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Bilous N, Abramenko I, Kryachok I, Bazyka D, Chumak A, Bebeshko V. Significance of VH genes mutation status for prognosis of CLL patients. Exp Oncol 2005; 27:325-9. [PMID: 16404355] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
AIM The aim of this study was to evaluate significance of VH mutation status for prognosis of B-cell chronic lymphocytic leukemia (B-CLL) patients in comparison with other prognostic markers. MATERIALS AND METHODS The VH mutation status was evaluated in 43 B-CLL patients by RT-PCR amplification and nucleotide sequencing, and CD38 expression - by two-color FACS analysis. The prognostic influence of VH mutation rate and CD38 expression level was tested by different statistical methods. RESULTS The increasing number of advanced cases over the follow-up period, shorter median time from diagnosis to start of second line therapy, worse response to fludarabine treatment, poor survival for early stages B-CLL were found in unmutated versus mutated CLL patients. The significance of CD38 expression for CLL prognosis was revealed as predictor for response for fludarabine treatment and time of progression in advanced stages. The correlation between CD38 expression and VH mutation status was not found. CONCLUSION Simultaneous determination of VH mutation status and CD38 expression may be helpful for prediction of CLL prognosis.
Collapse
MESH Headings
- ADP-ribosyl Cyclase 1/biosynthesis
- Adult
- Aged
- Antineoplastic Agents/therapeutic use
- Biomarkers, Tumor/analysis
- Female
- Flow Cytometry
- Humans
- Immunoglobulin Heavy Chains/genetics
- Immunoglobulin Variable Region/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Male
- Middle Aged
- Mutation
- Prognosis
- Reverse Transcriptase Polymerase Chain Reaction
- Vidarabine/analogs & derivatives
- Vidarabine/therapeutic use
Collapse
Affiliation(s)
- N Bilous
- Scientific Research Centre for Radiation Medicine, AMS of Ukraine, Kyiv, Ukraine.
| | | | | | | | | | | |
Collapse
|